128 related articles for article (PubMed ID: 23146028)
1. PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome.
Estevez-Garcia P; Castaño A; Martin AC; Lopez-Rios F; Iglesias J; Muñoz-Galván S; Lopez-Calderero I; Molina-Pinelo S; Pastor MD; Carnero A; Paz-Ares L; Garcia-Carbonero R
BMC Cancer; 2012 Nov; 12():514. PubMed ID: 23146028
[TBL] [Abstract][Full Text] [Related]
2. Platelet-derived growth factor (PDGF) cross-signaling via non-corresponding receptors indicates bypassed signaling in colorectal cancer.
Moench R; Gasser M; Nawalaniec K; Grimmig T; Ajay AK; de Souza LCR; Cao M; Luo Y; Hoegger P; Ribas CM; Ribas-Filho JM; Malafaia O; Lissner R; Hsiao LL; Waaga-Gasser AM
Oncotarget; 2022 Oct; 13():1140-1152. PubMed ID: 36264073
[TBL] [Abstract][Full Text] [Related]
3. Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy.
Berardi R; Brunelli A; Pagliaretta S; Paolucci V; Conti A; Goteri G; Refai M; Pompili C; Marcantognini G; Morgese F; Ballatore Z; Savini A; De Lisa M; Caramanti M; Santoni M; Zizzi A; Piva F; Mazzanti P; Onofri A; Sabbatini A; Scarpelli M; Cascinu S
Oncotarget; 2015 Aug; 6(22):19305-15. PubMed ID: 26254278
[TBL] [Abstract][Full Text] [Related]
4. PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy.
Wehler TC; Frerichs K; Graf C; Drescher D; Schimanski K; Biesterfeld S; Berger MR; Kanzler S; Junginger T; Galle PR; Moehler M; Gockel I; Schimanski CC
Oncol Rep; 2008 Mar; 19(3):697-704. PubMed ID: 18288404
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression.
Carvalho I; Milanezi F; Martins A; Reis RM; Schmitt F
Breast Cancer Res; 2005; 7(5):R788-95. PubMed ID: 16168125
[TBL] [Abstract][Full Text] [Related]
6. [Expression and clinical significance of PDGFRalpha and PDGFRbeta in colorectal cancer].
Zhu HT; Han J; Ma L
Ai Zheng; 2008 Jun; 27(6):654-60. PubMed ID: 18570744
[TBL] [Abstract][Full Text] [Related]
7. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K
Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026
[TBL] [Abstract][Full Text] [Related]
8. Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations.
Liegl B; Gülly C; Reich O; Nogales FF; Beham A; Regauer S
Histopathology; 2007 Mar; 50(4):448-52. PubMed ID: 17448020
[TBL] [Abstract][Full Text] [Related]
9. Blockade of the PDGFR family together with SRC leads to diminished proliferation of colorectal cancer cells.
Kaulfuß S; Seemann H; Kampe R; Meyer J; Dressel R; König B; Scharf JG; Burfeind P
Oncotarget; 2013 Jul; 4(7):1037-49. PubMed ID: 23900414
[TBL] [Abstract][Full Text] [Related]
10. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS
Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568
[TBL] [Abstract][Full Text] [Related]
11. Dysregulated PDGFR alpha expression and novel somatic mutations in colorectal cancer: association to RAS wild type status and tumor size.
Ben Jemii N; Tounsi-Kettiti H; Yaiche H; Mezghanni N; Jaballah Gabteni A; Fehri E; Ben Fayala C; Abdelhak S; Boubaker S
J Transl Med; 2020 Nov; 18(1):440. PubMed ID: 33213472
[TBL] [Abstract][Full Text] [Related]
12. K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRalpha in colorectal cancer.
Schimanski CC; Zimmermann T; Schmidtmann I; Gockel I; Lang H; Galle PR; Moehler M; Berger MR
Int J Colorectal Dis; 2010 Feb; 25(2):181-6. PubMed ID: 19936766
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of PDGFRalpha/beta genes in core binding factor leukemia with eosinophilia.
Monma F; Nishii K; Lorenzo F; Usui E; Ueda Y; Watanabe Y; Kawakami K; Oka K; Mitani H; Sekine T; Tamaki S; Mizutani M; Yagasaki F; Doki N; Miyawaki S; Katayama N; Shiku H
Eur J Haematol; 2006 Jan; 76(1):18-22. PubMed ID: 16343267
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis and angiogenic tyrosine kinase receptor expression in pediatric brain tumors.
Virág J; Kenessey I; Haberler C; Piurkó V; Bálint K; Döme B; Tímár J; Garami M; Hegedűs B
Pathol Oncol Res; 2014 Apr; 20(2):417-26. PubMed ID: 24190638
[TBL] [Abstract][Full Text] [Related]
15. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
[TBL] [Abstract][Full Text] [Related]
16. The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence.
Jansson S; Aaltonen K; Bendahl PO; Falck AK; Karlsson M; Pietras K; Rydén L
Breast Cancer Res Treat; 2018 Jun; 169(2):231-241. PubMed ID: 29380207
[TBL] [Abstract][Full Text] [Related]
17. Platelet‑derived growth factor receptor‑β gene expression relates to recurrence in colorectal cancer.
Fujino S; Miyoshi N; Ohue M; Takahashi Y; Yasui M; Hata T; Matsuda C; Mizushima T; Doki Y; Mori M
Oncol Rep; 2018 May; 39(5):2178-2184. PubMed ID: 29498405
[TBL] [Abstract][Full Text] [Related]
18. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
19. A MLH1 polymorphism that increases cancer risk is associated with better outcome in sporadic colorectal cancer.
Nejda N; Iglesias D; Moreno Azcoita M; Medina Arana V; González-Aguilera JJ; Fernández-Peralta AM
Cancer Genet Cytogenet; 2009 Sep; 193(2):71-7. PubMed ID: 19665066
[TBL] [Abstract][Full Text] [Related]
20. Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma.
Patel SH; Kneuertz PJ; Delgado M; Kooby DA; Staley CA; El-Rayes BF; Kauh JS; Sarmiento JM; Hanish S; Cohen C; Farris AB; Maithel SK
Ann Surg Oncol; 2011 Nov; 18(12):3384-90. PubMed ID: 21590454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
